Correlation Between Inozyme Pharma and Solid Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Solid Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Solid Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Solid Biosciences LLC, you can compare the effects of market volatilities on Inozyme Pharma and Solid Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Solid Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Solid Biosciences.

Diversification Opportunities for Inozyme Pharma and Solid Biosciences

0.82
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Inozyme and Solid is 0.82. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Solid Biosciences LLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Solid Biosciences LLC and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Solid Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Solid Biosciences LLC has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Solid Biosciences go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Solid Biosciences

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Solid Biosciences. But the stock apears to be less risky and, when comparing its historical volatility, Inozyme Pharma is 1.23 times less risky than Solid Biosciences. The stock trades about -0.27 of its potential returns per unit of risk. The Solid Biosciences LLC is currently generating about -0.14 of returns per unit of risk over similar time horizon. If you would invest  753.00  in Solid Biosciences LLC on September 14, 2024 and sell it today you would lose (285.00) from holding Solid Biosciences LLC or give up 37.85% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Inozyme Pharma  vs.  Solid Biosciences LLC

 Performance 
       Timeline  
Inozyme Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Solid Biosciences LLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Solid Biosciences LLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Inozyme Pharma and Solid Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inozyme Pharma and Solid Biosciences

The main advantage of trading using opposite Inozyme Pharma and Solid Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Solid Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Solid Biosciences will offset losses from the drop in Solid Biosciences' long position.
The idea behind Inozyme Pharma and Solid Biosciences LLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings